Parkinson’s Disease Therapeutics Market to 2019 – Pipeline Shows Shift Towards Long Term Disease Management...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 8
2.1 Overview 8
2.2 Epidemiology 8
2.3 Etiology 9
2.3.1 Loss of Dopaminergic Neurons 9
2.3.2 Genetic Factors 9
2.3.3 Exposure to Environmental Toxins 9
2.4 Pathophysiology 10
2.4.1 Pathophysiological Changes in Basal Ganglia in Parkinson’s Disease 12
2.4.2 Pathophysiological Changes Involved in the Rise of Motor Complications in Parkinson’s Disease 12
2.5 Symptoms 13
2.6 Co-morbidities and Complications 14
2.7 Diagnosis 14
2.7.1 Classification 15
2.8 Prognosis and Disease Staging 19
2.9 Treatment Options 20
2.9.1 Pharmacological Treatment 20
2.9.2 Non-pharmacological Treatments 22
2.9.3 Treatment Algorithm 23
3 Marketed Products 27
3.1 Therapeutic Landscape 28
3.1.1 Dopamine Replacement Therapies 28
3.1.2 MAO-B inhibitors 32
3.1.3 Dopamine Agonists 34
3.1.4 COMT Inhibitors 44
3.1.5 Nouriast (istradefylline) – Kyowa Hakko Kirin 46
3.1.6 Exelon (rivastigmine tartrate) – Novartis AG 46
3.1.7 Symmetrel (amantadine hydrochloride) – Alliance Pharma Plc 48
3.1.8 Other drugs targeting non-motor symptoms of PD 49
3.2 Comparative Efficacy and Safety 50
3.3 Unmet Need 54
4 Pipeline for Parkinson’s Disease 55
4.1 Overall Pipeline 55
4.2 Molecular Targets in Parkinson’s Disease Pipeline 57
4.3 Clinical Trials 60
4.3.1 Failure Rate of Developmental Pipeline 60
4.3.2 Clinical Trial Sizes 63
4.3.3 Clinical Trial Duration 64
4.3.4 Summary of Clinical Trial Cost and Risk Analyses 66
4.4 Promising Candidates in Pipeline 67
4.4.1 Rytary (carbidopa, levodopa) – Impax Laboratories, Inc. 67
4.4.2 Safinamide – Newron Pharmaceuticals S.p.A 67
4.4.3 Pimavanserin – Acadia Pharmaceuticals Inc. 68
4.4.4 Tozadenant – Biotie Therapies 69
4.4.5 Mavoglurant – Novartis AG 69
4.4.6 Dipraglurant – Addex Therapeutics 70
4.5 Heat Map of Safety and Efficacy for Parkinson’s Disease Pipeline and Marketed Products 71
5 Market Forecast to 2019 75
5.1 Geographical Markets 75
5.1.1 Global Market 76
5.1.2 North America 78
5.1.3 Top Five Countries of Europe 81
5.1.4 Japan 85
5.2 Drivers and Barriers 87
5.2.1 Drivers 87
5.2.2 Barriers 88
6 Deals and Strategic Consolidations 90
6.1 Major Co-development Deals 90
6.1.1 Newron Pharmaceuticals S.p.A. Enter Agreement with Zambon Company S.p.A. 92
6.1.2 QR Pharma, Inc. Enter Research Agreement with Massachusetts General Hospital 93
6.1.3 Ceregene, Inc. Enter Agreement with Genzyme Corporation 93
6.2 Major Licensing Deals 93
6.2.1 Biotie Therapies Corp. Enter Worldwide Agreement with UCB Group 96
6.2.2 Ono Pharmaceutical Co., Ltd. Enter Agreement with Bial – Portela & Ca, S.A 96
6.2.3 Domain Therapeutics S.A. Enter Agreement with Prexton Therapeutics 97
6.2.4 Newron Pharmaceuticals S.p.A. Enter Agreement with Zambon Company S.p.A. 97
6.2.5 Oncodesign SA Enter Agreement with Ipsen S.A. 97
6.2.6 Cephalon, Inc. Enter Licensing Agreement with Mesoblast Limited 97
6.2.7 Shire Pharmaceutical Group Plc Enter Agreement with Heptares Therapeutics Ltd. 98
7 Appendix 99
7.1 All Pipeline Products, by Phase 99
7.2 Sources 116
7.3 Market Definition 125
7.4 Abbreviations 125
7.5 Research Methodology 127
7.5.1 Coverage 127
7.5.2 Secondary Research 127
7.6 Therapeutic Landscape 128
7.7 Epidemiology-Based Forecasting 128
7.8 Market Size by Geography 129
7.9 Geographical Landscape 130
7.10 Pipeline Analysis 130
7.11 Competitive Landscape 130
7.11.1 Expert Panel Validation 130
7.12 Contact Us 130
7.13 Disclaimer 130